←
Brain Inflammation Collaborative3,623 posts
Brain Inflammation Collaborative avatar

Brain Inflammation Collaborative

@BrainInflCollab

uniting patients, researchers & clinicians to advocate & research 30+ neuroinflammation-linked conditions with overlapping symptoms, causes & responses.

◷ Joined June 2023▧ 1,062 Photos and videos
Brain Inflammation Collaborative avatar
Brain Inflammation Collaborative@BrainInflCollab·Nov 14

More rigorous trials are still needed, but the shift toward targeting a possible autoimmune root cause represents meaningful progress for a condition long overlooked. The full article is in the comment section of this post. #POTS #LongCOVID #Autoimmune #Dysautonomia Literature Cited: 1. Dulal, D. et al. Eur Heart J Qual Care Clin Outcomes. Aug 2025. PMID: 39775762 Read more here:

Brain Inflammation Collaborative avatar
Brain Inflammation Collaborative@BrainInflCollab·Nov 14

Current standards of care focus on symptom management (salt restriction, fluid intake, compression garments, beta-blockers). Now, specialists are beginning to trial immunomodulatory drugs used to treat conditions characterized by the immune system's attack on healthy tissues (autoimmunity). “We are beginning studies to look at the effects of using the same medications that are employed to treat rheumatologic disorders,” Grubb said. “Why reinvent the wheel? Let’s try to do what they do.”

Brain Inflammation Collaborative avatar
Brain Inflammation Collaborative@BrainInflCollab·Nov 14

Worldwide data show a 130% increase in POTS diagnoses at the start of the COVID-19 pandemic (1). “I’d been seeing POTS patients for 30 years, and suddenly we were inundated with them,” said Dr. Blair Grubb, an autonomic disorders specialist. Many POTS cases appear to be post-viral, often after failing to fully recover from COVID-19 (Long COVID). Evidence suggests that in a subset of these patients, autoantibodies may be driving the condition...🧵

Post attachment
Brain Inflammation Collaborative avatar
Brain Inflammation Collaborative@BrainInflCollab·Nov 12

A new drug called Kamuvudine (K-9) has shown the ability to reverse some of the damage caused by multiple sclerosis in preclinical studies. University of Virginia researchers found that, unlike current MS treatments that mainly prevent new attacks, K-9 targets specific immune pathways (inflammasomes) that damage nerve fibers and myelin. In mice that already had paralysis and vision loss, treatment with K-9 led to recovery of movement and vision. Human data on related drugs also look encouraging, and K-9 has already been tested for safety in other conditions. Clinical trials in people with MS are the critical next step. Still early days, but this is a hopeful development for the MS community. #MultipleSclerosis #MSResearch Read more here: buff.ly/AeXOEbg

Post attachment
Brain Inflammation Collaborative avatar
Brain Inflammation Collaborative@BrainInflCollab·Nov 10

Patients with hypermobile Ehlers-Danlos syndrome (hEDS) face nearly 3x the risk of developing Long COVID, according to a major U.S. nationwide study of 19+ million health records. Despite similar COVID infection rates, the elevated risk of developing Long COVID was heavily concentrated in hEDS patients who were also diagnosed with: - POTS - MCAS - ME/CFS The study also found hEDS is far more common than previously thought (~1 in 800 people). Better screening, earlier diagnosis, and integrated care are urgently needed for this underdiagnosed group. #hEDS #LongCOVID #POTS #MCAS #EhlersDanlos Read more: buff.ly/SphJNeW

Post attachment
Brain Inflammation Collaborative avatar
Brain Inflammation Collaborative@BrainInflCollab·Nov 7

People with hEDS and HSD are often told their symptoms don’t have a clear biological basis: no universal gene, no simple lab test, just “loose joints.” Research from the Colombi Lab examined the skin cells of these patients and has found something unexpected: the fibroblasts don’t behave like ordinary repair cells. The differences might provide an objective cellular signature for conditions that have long been dismissed or misunderstood. Learn what the cells are actually doing and why it matters for tissue fragility in our latest Substack article below.

Post attachment
Brain Inflammation Collaborative avatar
Brain Inflammation Collaborative@BrainInflCollab·Nov 6

A subset of individuals with depression (1), sleep disorders (2), bipolar disorder (3), or mood disorders (1) have all been found to have elevated pro-inflammatory cytokines in their blood. The study referenced in the infographic is yet another example of why immunopsychiatry remains an active area of research. We recently removed the paywall from a recent Substack article explaining how inflammation in the body can affect our mental health. Access it for free here: buff.ly/o0wpjRp (For those of you who are paid Substack members, keep an eye out for our next article examining the crosstalk between myofibroblasts and mast cells in those with hypermobility spectrum disorder (HSD) and hEDS.) Literature Cited: 1. Felger JC. Curr Neuropharmacol. 2018. PMID: 29173175 2. Zielinski MR, Gibbons AJ. Front Cell Infect Microbiol. 2022. PMID: 35392608 3. Dolsen MR, Soehner AM, Harvey AG. Psychosom Med. Jan 2018. PMID: 28914726

Post attachment
Brain Inflammation Collaborative avatar
Brain Inflammation Collaborative@BrainInflCollab·Nov 3

If you have experienced any of these issues, please let us know. We developed a digital health tool to help patients have a more productive conversation with their physician by helping unhide patterns in their health. It also allows users to tap into current and clinical research projects.

Post attachment
Brain Inflammation Collaborative avatar
Brain Inflammation Collaborative@BrainInflCollab·Nov 3

This paper did find that clinicians are highly motivated to improve their standard of care for neuropsychiatric symptoms. The first step is for physicians to appreciate how common these symptoms are so they can be promptly identified and successfully treated.

Brain Inflammation Collaborative avatar
Brain Inflammation Collaborative@BrainInflCollab·Nov 3

This paper reveals what we at the Brain Inflammation Collaborative have been posting about for years on social media: 1. Chronic inflammation can increase your risk of psychiatric and neurological issues. 2. Clinicians collectively fail to appreciate the power of this association. These same neuropsychiatric symptoms are common in other conditions of interest to us, including: - Neurodegenerative diseases - Long COVID - ME/CFS - MCAS - PANS - EDS - etc.

Post attachment